Formats
  1. Journal Article (66894)
  2. Meeting Abstract (33621)
  3. Book Section (5097)
  4. Review (3749)
  5. Editorial (2165)
  6. Conference Paper (1526)
  7. Correspondence (663)
  8. Guidelines (661)
  9. Research Letter (548)
  10. Book Whole (344)
  11. Miscellaneous (339)
Groups
  1. Department of Medicine (39043)
  2. GSK Faculty (22462)
  3. Solid Tumor Oncology Division (22061)
  4. Surgery (21262)
  5. Survivorship Research (15766)
  6. Sloan Kettering Institute Faculty (15652)

More Groups

People
  1. Marc Ladanyi (1327)
  2. Robert Motzer (1243)
  3. Victor Reuter (1228)
  4. Howard Scher (1130)
  5. Murray Brennan (1059)
  6. Sergio Giralt (1050)

More People

Years
  1. 2025 (2139)
  2. 2024 (5384)
  3. 2023 (5806)
  4. 2022 (6169)
  5. 2021 (5714)
  6. 2020 (5618)

More Years

Publications
  1. Journal of Clinical Oncology (8590)
  2. Blood (4951)
  3. Cancer Research (2701)
  4. International Journal of Radiation Oncology, Biology, Physics (2611)
  5. Laboratory Investigation (1879)
  6. Modern Pathology (1814)

More Publications

Publishers
  1. Elsevier Inc. (13846)
  2. American Society of Clinical Oncology (9169)
  3. Springer (7192)
  4. Nature Publishing Group (6375)
  5. American Association for Cancer Research (6014)
  6. Elsevier Science, Inc. (5512)

More Publishers

Results (115607)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Lisocabtagene maraleucel (liso-cel) in R/R MCL: Primary analysis results from the mcl cohort of the single-arm, multicenter, phase I seamless design TRANSCEND NHL 001 study
    Meeting Abstract

    Palomba, M. L.; Siddiqi, T.; Gordon, L. I.; Kamdar, M.; Lunning, M.; Hirayama, A. V.; Abramson, J. S.; Arnason, J.; Ghosh, N.; Mehta, A.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Epcoritamab + R-CHOP in patients with previously untreated (1L) high-risk diffuse large B-cell lymphoma, including double-hit/triple-hit lymphoma: Updated EPCORE NHL-2 data
    Meeting Abstract

    Falchi, L.; Clausen, M. R.; Offner, F.; de Vos, S.; Brody, J.; Linton, K. M.; Snauwaert, S.; Cordoba, R.; Wu, J.; Bykhovski, I.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Five-year efficacy and safety of tafasitamab in patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL): Final results from the phase II L-MIND study
    Meeting Abstract

    Duell, J.; Abrisqueta, P.; Andre, M.; Augustin, M.; Gaidano, G.; Barca, E. G.; Jurczak, W.; Kalakonda, N.; Liberati, A. M.; Maddocks, K. J.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Five-year subgroup analysis of tafasitamab + lenalidomide from the phase II L-MIND study in patients with relapsed or refractory diffuse large B-cell lymphoma
    Meeting Abstract

    Duell, J.; Abrisqueta, P.; Dreyling, M.; Gaidano, G.; Barca, E. G.; Jurczak, W.; Maddocks, K. J.; Menne, T.; Nagy, Z.; Tournilhac, O.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Phase III trial of subcutaneous epcoritamab + R-CHOP versus R-CHOP alone in patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL): EPCORE DLBCL-2
    Meeting Abstract

    Sehn, L.; Chamuleau, M.; Lenz, G.; Clausen, M.; Haioun, C.; Izutsu, K.; Davies, A.; Zhu, J.; Oki, T.; Szafer-Glusman, E.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • TRANSCEND FL: Phase II study results of lisocabtagene maraleucel (liso-cel) in patients with R/R follicular lymphoma (FL)
    Meeting Abstract

    Nastoupil, L. J.; Dahiya, S.; Palomba, M. L.; Garcia-Sancho, A. M.; Ortega, J. L. R.; Kuruvilla, J.; Jager, U.; Cartron, G.; Izutsu, K. I.; Dreyling, M.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Responses with asciminib continue to deepen over time in patients with chronic myeloid leukemia in chronic phase (CML-CP) after ≥2 prior tyrosine kinase inhibitors (TKIs) in the phase III ASCEMBL study
    Meeting Abstract

    Mauro, M.; Hochhaus, A.; Hughes, T.; Rea, D.; Boquimpani, C.; Minami, Y.; Apperley, J.; Garcia-Gutiérrez, V.; Kapoor, S.; Espurz, N.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • First-in-human phase I study of ELVN-001, an oral, selective BCR::ABL1 tyrosine kinase inhibitor, in patients with chronic myeloid leukemia who failed prior tyrosine kinase inhibitors
    Meeting Abstract

    Mauro, M.; Lang, F. B.; Kim, D. W.; Heinrich, M.; Sasaki, K.; Lyssikatos, J.; Collins, H.; Hochhaus, A.
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • ASC2ESCALATE: A US, phase II open-label, single-arm, dose-escalation study of asciminib monotherapy in second-line (2L) and first-line (1L) treatment of patients with chronic myeloid leukemia in chronic phase (CML-CP)
    Meeting Abstract

    Atallah, E.; Mauro, M.; Sasaki, K.; Levy, M.; Koller, P.; Yang, D.; Laine, D.; Sabo, J.; Gu, E. N.; Cortes, J.
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • SVR (spleen volume reduction) predicts OS (overall survival) in MF (myelofibrosis) patients on PAC (pacritinib) but not BAT (best available therapy): PERSIST-2 landmark OS analysis
    Meeting Abstract

    Ajufo, H.; Bewersdorf, J. P.; Harrison, C.; Palandri, F.; Mascarenhas, J.; Palmer, J.; Gerds, A.; Kiladjian, J. J.; Buckley, S.; Derkach, A.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save